Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027627 (metastases)
 103,950 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Metastases are an uncommon cause of tumor in the sellar region. We report two cases of small cell lung cancer presenting with visual loss and hypopituitarism resulting from metastasis to the pituitary area.
Rev Mal Respir 2000 Dec
PMID:[Symptomatic hypothalamo-hypophyseal metastasis revealing a small-cell bronchial carcinoma. Study of two cases]. 1121 9

We report 5 cases of sarcoidosis in 4 men and 1 woman who presented multinodular pulmonary lesions. Seldom described (1 to 4% of all cases of sarcoidosis), a multinodular pulmonary presentation is suggestive of metastatic disease. In our patients, the parenchymal opacities were multiple, peripheral and exhibited fuzzy limits, measuring 1 to 7 cm in size and frequently associated with mediastinal adenopathies. The radiographic pattern contrasted with the clinical manifestations (3 of the 5 cases were fortuitous discoveries). Pathological proof required to rule out other disease, especially tumor formation, was acquired; mediastinoscopy allowing the diagnosis in 3 out of 5 cases. The clinical course was favorable in all cases without treatment within 8 +/- 5 months and a mean follow-up of 5 years (range 9 months to 14 years).
Rev Mal Respir 2001 Apr
PMID:[Pseudotumoral forms of sarcoidosis]. 1142 14

The authors report the case of a cardiac metastasis of a Market cell skin tumour in a 72 year old woman, presenting with chest pain and infero-lateral myocardial ischaemia simulating an acute coronary syndrome. The diagnosis, suspected on echocardiography, was confirmed by thoracic CT scan. Markel cell carcinoma is a rare skin tumour classified among the malignant neuroendocrine tumours. It has a high metastatic potential, especially to the gastrointestinal tract and the lung. On the other hand, cardiac metastases are quite exceptionally rare.
Arch Mal Coeur Vaiss 2001 Dec
PMID:[Cardiac metastasis from a Merkel cell skin carcinoma. A case report]. 1182 30

The purpose of this study was to investigate the utility of 18fluorodeoxyglucose (FDG) coincidence detection position emission tomography (CDET) in the evaluation of metastatic mediastinal lymph nodes in patients with potentially operable non-small-cell lung cancer (NSCLC). A prospective study was performed in thirty patients with newly suspected NSCLC. Thoracic computed tomography (CT), FDG CDET, and invasive surgical staging were performed in patients. Blinded prospective interpretation was performed for each test and compared to pathological staging obtained by mediastinoscopy and/or by thoracotomy. Patients were followed for six months to detect occult metastases. The sensitivity and specificity of CDET for the detection of mediaStinal lymph nodes were 75% and 94.4% respectively. The corresponding value for CT were 50% and 80.9%. Three patients with N1 disease were classified as N0 by CDET. With regard to definitive surgical node staging, CDET could identify nodal disease in 26 patients and CT only in 18 patients (n = 30). FDG full-ring positron emission tomography (PET) is the most accurate non-invasive method for the detection and staging of lung cancer. In addition, FDG CDET shows high accuracy for the detectability of pulmonary lesions with a diameter at least 2 cm and the evaluation of lymph node in NSCLC.
Rev Mal Respir 2001 Dec
PMID:[Value of 18FDG-CDET in the evaluation of operable bronchial cancer]. 1192 80

Meningeal metastases from malignant mesotheliomas are rarely observed. We report the case of a 54-year-old man with an asymptomatic pleural effusion and simultaneous sensitive and motor disorders of the right hemibody. A meningeal localization of a pleural malignant mesothelioma was discovered and confirmed by a comparative immuno-histological analysis. Here we present a differential diagnosis and a review of the literature to give prominence to diagnostic pitfalls in this rare disease.
Rev Mal Respir 2001 Dec
PMID:[Meningeal metastasis of pleural mesothelioma]. 1192 90

A 68-year old woman was hospitalised because of isolated right heart failure. Doppler echocardiography revealed severe tricuspid regurgitation with thickened, shortened, hypomobile leaflets. Pulmonary valve was thickened with mild pulmonary regurgitation. Mitral and aortic valves were normal. The patient was finally diagnosed with carcinoid heart disease from an isolated ovarian carcinoid cancer without hepatic metastases. Ovarectomy was performed and the patient was considered cured of her cancer. Because of refractory right heart failure, she underwent tricuspid valve replacement with a bioprosthesis. Such cardiovascular manifestations are rarely the presenting symptoms of carcinoid disease. Carcinoid heart disease from ovarian primary cancer is exceptional. In this circumstance, carcinoid cardiac lesions may develop in the absence of hepatic metastases because the venous blood from the ovaries drains into the inferior vena cava without hepatic first past effect. Surgical resection of primary ovarian carcinoid tumor is often curative and the prognosis depends mainly on the cardiac condition. The diagnosis of carcinoid syndrome should be discussed in patients with organic tricuspid regurgitation without left valvular disease.
Arch Mal Coeur Vaiss 2003 Feb
PMID:[Isolated carcinoid tumor of the ovary disclosed by tricuspid insufficiency]. 1462 39

The goal of mediastinal sampling or a radical lymph node resection after lung cancer resection is to correctly stage the illness to enable a more accurate assessment of prognosis. Metastasis to mediastinal nodes may be encountered even in small peripheral T1 tumours. Radical lymph node resection often uncovers metastases that would have been missed by mediastinal sampling alone. The morbidity associated with radical node resection is very low, and long term survival appears to be improved, compared with node sampling. At present, lymph node staging has little influence on the choice of adjuvant treatments.
Rev Mal Respir 2005 Dec
PMID:[Lymph node clearance]. 1634 Aug 44

Pre-operative chemotherapy for non-small cell bronchial carcinoma (NSCLC) has the twin objectives of destruction of micrometastases and increased resectabilty of the primary tumour. The trials of Rosell and Roth showed weak benefits in favour of the combination. In the French trial overall survival was no different for the whole group but was improved in early stage disease. Preliminary results of the SWOG trial show a non-significant difference in 2 year survival of 6%. The EORTC 08941 trial showed no difference between surgery and radiotherapy following induction chemotherapy in non-resectable stage IIIAN2 NSCLC. The INT-0139 trial compared surgery following induction chemo-radiotherapy with chemo-radiotherapy alone. There was no difference between the two strategies but analysis of sub-groups suggested that some groups might benefit from the triple combination. Two further trials await publication. The small number of patients in each trial suggests that a meta-analysis will be necessary to reach a definite conclusion. The combination of surgery and chemotherapy is becoming standard in stage II disease. Only the timing, pre- or post-operative, remains controversial. At present, of the original objectives, only the destruction of micro-metastases has been confirmed.
Rev Mal Respir 2005 Dec
PMID:[Pre-operative chemotherapy in non-small cell lung cancer]. 1634 Aug 46

Bronchioloalveolar carcinoma (BAC) is a primary pulmonary adenocarcinoma (ADC) arising in the cells of the terminal respiratory unit. Its restrictive definition adopted by the 1999 WHO pathological classification requires a complete surgical resection of the tumour to exclude any signs of invasion. Although stage IIIB and IV tumours were excluded from the strict WHO definition of BAC the first international workshop on this tumour in 2004 emphasised the clinico-pathological continuum that exists between BAC as defined by WHO and ADC with BAC features (ADC-BAC). BAC and ADC-BAC are distinguished from other non-small cell carcinomas by an increased incidence in women, non-smokers and Asians. The predominant spread through the airways explains the frequent presentation as diffuse or multifocal consolidation and death is more often due to bilateral pulmonary infiltration than extra-thoracic metastases. Progression is slower and the prognosis better than that of other ADC. Surgery offers the best treatment for localised disease. The high frequency of epidermal growth factor receptor (EGFR) expression and amplification and/or mutation of its gene, as well as the finding in some cases of a major response to EGFR tyrosine-kinase inhibitors, have lead to several therapeutic trials of these drugs. However, the place of chemotherapy has recently been reviewed.
Rev Mal Respir 2006 Nov
PMID:[Clinical types of thoracic cancer. Bronchiolo-alveolar carcinoma and adenocarcinoma with bronchioloalveolar features: a clinico-pathological spectrum]. 1726 53

Small cell carcinomas represent less than 20% of all lung cancer. Only a third of these patients present with limited stage disease. Treatment is based on a combination of chemotherapy and radiotherapy including a platinum salt with or without another drug. Conformational thoracic radiotherapy is administered either classically fractionated or in an accelerated form. Prophylactic cranial irradiation is indicated in patients with a good response. An improvement in outcomes has been obtained with this regimen. Even in limited stage disease 5 year survival remains about 25% in the best series. The majority of patients will relapse and the risk of cerebral metastases is particularly high, reaching nearly 50% at 2 years even in patients with a complete response. Prophylactic cranial irradiation should be part of the standard management of patients with a complete response on the basis of a meta analysis showing a 5% increase in survival at three years. Even though combination treatments have improved survival, a number of questions remain that should stimulate further clinical trials to establish the optimum regimes of chemotherapy and radiotherapy and the optimum strategies for combining the two. In addition the potential role of targeted therapy in selected patients must be examined.
Rev Mal Respir 2006 Nov
PMID:[Small cell lung cancer (CPC). Management of patients presenting with limited stage small cell carcinoma of the lung]. 1726 57


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>